The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

March was a light month across the board for hires news, but the digital and supplier sectors in biopharma saw a spat of ...